Earlier this week the FDA granted accelerated approval to palbociclib for the treatment of advanced (metastatic) breast cancer in combination with letrozole. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby suppressing tumor cell proliferation.
Over the past decade, researchers at Weill Cornell have led investigations of palbociclib in multiple myeloma and mantle cell lymphoma, including an ongoing phase I trial of palbociclib in combination with ibrutinib for patients with previously treated mantle cell lymphoma. Additional trials are planned.
Please look to this space for further updates concerning palbociclib for lymphoma patients. A full listing of available clinical trials can be found on our clinical trials page.